Yıl: 2011 Cilt: 7 Sayı: 2 Sayfa Aralığı: 47 - 67 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Meme kanserinde risk faktörleri, riskin değerlendirilmesi ve prevansiyon: İstanbul 2010 konsensus raporu

Öz:
Meme kanseri kadınlarda görülen en sık kanser tipidir ve kadınlarda ölüme neden olan kanserler arasında da 2. sırada gelir. Meme kanseri ile ilişkili birçok risk faktörü tanımlanmıştır. Bu risk faktörleri demografik (yaş, etnisite/ırk), reprodüktif öykü (menarş yaşı, parite, ilk canlı doğum yaşı, menapoz yaşı), ailesel/genetik faktörler (aile öyküsü, meme kanseri riski ile ilişkili olduğu bilinen veya şüphe edilen BRCA 1/2, p53, PTEN veya diğer gen mutasyonları), çevresel faktörler (30 yaşından önce toraks bölgesine radyoterapi [örneğin Hodgkin hastalığı tedavisi nedeniyle], hormon replasman tedavisi, alkol kullanımı) ve diğer faktörler (meme biyopsi sayısı, atipik hiperplazi veya lobular karsinoma in situ [LCIS], dens meme yapısı, vücut kitle indeksi [BMI]) olarak sınıflandırılabilir. Her kadının meme kanseri riskini tahmin etmek zordur. Mevcut risk faktörlerinden çok az bir bölümü modifiye edilebilir özellikte olduğu için meme kanseri insidansını azaltmaya yönelik etkili stratejilerin geliştirilmesi oldukça güçtür. Yaşam tarzında yapılacak bazı değişiklikler meme kanseri riskinde azalmaya neden olabilir. Düzenli mamografi çekilmesi ile meme kanseri gelişimi açısından yüksek risk grubundaki bazı kadınlarda anlamlı bir risk azalması sağlanamasa bile, meme kanserine bağlı ölümlerde azalma elde edilecektir. Yüksek riskli kadınlarda 5 yıl süreyle tamoksifen veya raloksifen kullanılması meme kanseri riskinde yaklaşık %50 azalma sağlayacaktır. Risk azaltıcı cerrahi yüksek riskli kadınlar için bir diğer alternatifi oluşturmaktadır ve ancak multidisipliner konsültasyonlar yapıldıktan sonra düşünülmelidir.
Anahtar Kelime:

Konular: Onkoloji

Risk factors in breast cancer, risk assessment and prevention: 2010 Istanbul consensus meeeting report

Öz:
Breast cancer is the most common female cancer and the second most common cause of cancer death in women. Many risk factors have been associated with breast cancer. These can be grouped into categories including factors related to demographics (eg, age, ethnicity/race); reproductive history (age at menarche, parity, age at first live birth, age at menopause); familial/genetic factors (family history, known or suspected BRCA 1/2, p53, PTEN or other gene mutation associated with breast cancer risk); environmental factors (prior thoracic irradiation before age 30 [eg, to treat Hodgkin’s disease], hormone replacement therapy, alcohol consumption); and other factors (eg, number of breast biopsies, atypical hyperplasia or lobular carcinoma in situ [LCIS], breast density, body mass index [BMI]). Estimating breast cancer risk for the individual women is difficult. The development of effective strategies for the reduction of breast cancer incidence has also been difficult because of the few of the existing risk factors are modifiable. A number of lifestyle changes may reduce breast cancer risk. Even if breast cancer incidence cannot be substantially reduced for some women who are at high risk for developing the disease, the risk of death from breast cancer can be reduced by regular mammography screening. For women who are already at higher than average risk, their risk of developing breast cancer can be reduced by at least 50 percent or more by taking tamoxifen or raloxifene for five years. Risk reduction surgery is another option for high risk patients and should be considered after multidisiplinary consultations.
Anahtar Kelime:

Konular: Onkoloji
Belge Türü: Makale Makale Türü: Toplantı Özetleri Erişim Türü: Erişime Açık
  • 1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009; 59: 225-249.
  • 2. Tuncer M. Significance of cancer in Turkey, the burden of disease and cancer control policies (Volume 74). In: Tuncer M., eds. Cancer Control in Turkey, Ankara, Onur Press, Health Ministry Publication, 2008: 5-9.
  • 3. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer, 2009.
  • 4. Özmen V, Fidaner C, Aksaz E, ve ark. Meme Sağlığı Dergisi, 2009; 5: 125-134.
  • 5. Hsieh CC, Trichopoulos D, Katsouyanni K, Yuasa S. Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case-control study. Int J Cancer 1990; 46: 796-800.
  • 6. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses’ Health Study. Am J Epidemiol 2000; 152:950-964.
  • 7. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997; 350: 1047.
  • 8. Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: The Nurses’ Health Study. Am J Epidemiol 1994; 139: 819-835.
  • 9. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Risk of breast cancer in a cohort of infertile women. Gynecol Oncol 1996; 60: 3-7.
  • 10. Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J, Oelsner G, Freedman L, Mashiach S, Lunenfeld B. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1998; 147: 1038-1042.
  • 11. Beral V, Bull D, Doll R, Peto R, Reeves G; Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83,000 women with breast cancer from 16 countries. Lancet 2004; 363: 1007-1016.
  • 12. Melbye M, Wohlfahrt J, Olsen JH, Frisch M, Westergaard T, Helweg- Larsen K, Andersen PK. Induced abortion and the risk of breast cancer. N Engl J Med 1997; 336: 81-85.
  • 13. Erlandsson G, Montgomery SM, Cnattingius S, Ekbom A. Abortions and breast cancer: record-based case-control study. Int J Cancer 2003; 103: 676-679.
  • 14. Paoletti X, Clavel-Chapelon F. Induced and spontaneous abortion and breast cancer risk: results from the E3N cohort study. Int J Cancer 2003; 106: 270-276.
  • 15. Reeves GK, Kan SW, Key T, Tjønneland A, Olsen A, Overvad K, Peeters PH, Clavel-Chapelon F, Paoletti X, Berrino F, Krogh V, Palli D, Tumino R, Panico S, Vineis P, Gonzalez CA, Ardanaz E, Martinez C, Amiano P, Quiros JR, Tormo MR, Khaw KT, Trichopoulou A, Psaltopoulou T, Kalapothaki V, Nagel G, Chang-Claude J, Boeing H, Lahmann PH, Wirfält E, Kaaks R, Riboli E. Breast cancer risk in relation to abortion: Results from the EPIC study. Int J Cancer 2006; 119: 1741-1745.
  • 16. Michels KB, Xue F, Colditz GA, Willett WC. Induced and Spontaneous Abortion and Incidence of Breast Cancer Among Young Women: A Prospective Cohort Study. Arch Intern Med 2007; 167: 814-820.
  • 17. Stuebe AM, Willett WC, Xue F, Michels KB. Lactation and incidence of premenopausal breast cancer: a longitudinal study. Arch Intern Med 2009; 169: 1364-1371.
  • 18. Zheng T, Holford TR, Mayne ST, Owens PH, Zhang Y, Zhang B, Boyle P, Zahm SH. Lactation and breast cancer risk: a case-control study in Connecticut. Br J Cancer 2001; 84: 1472-1476.
  • 19. Tryggvadottir L, Tulinius H, Eyfjord JE, Sigurvinsson T. Breastfeeding and reduced risk of breast cancer in an Icelandic cohort study. Am J Epidemiol 2001; 154: 37-42.
  • 20. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 2002; 360: 187.
  • 21. Jernstrom H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C, Weber BL, Horsman D, Rosen B, Foulkes WD, Friedman E, Gershoni- Baruch R, Ainsworth P, Daly M, Garber J, Olsson H, Sun P, Narod SA. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2004; 96: 1094-1098.
  • 22. Lynch HT, Watson P, Conway TA, Lynch JF. Clinical/genetic features in hereditary breast cancer. Breast Cancer Res Treat 1990; 15: 63-71.
  • 23. Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: A systematic review and” meta-analysis. Int J Cancer 1997: 71: 800-809.
  • 24. Murff HJ, Spigel DR, Syngal S. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 2004; 292: 1480-1489.
  • 25. Colditz GA, Willett WC, Hunter DJ, Stampfer MJ, Manson JE, Hennekens CH, Rosner BA. Family history, age, and risk of breast cancer. JAMA 1993; 270: 338-343.
  • 26. Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk: The Utah population data-base. JAMA 1993; 270: 1563-1568.
  • 27. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001; 358: 1389.
  • 28. Ellisen L, Haber D. Hereditary breast cancer. Ann Rev Med 1998: 49: 425-436.
  • 29. NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast and Ovarian, 2009.
  • 30. Murff HJ, Byrne D, Syngal S. Cancer risk assessment: quality and impact of the family history interview. Am J Prev Ivied 2004; 27: 239-245.
  • 31. Domchek SM, Eisen A, Calzone K, Stopfer J, Blackwood A, Weber BL. Application of Breast Cancer Risk Prediction Models in Clinical Practice. Journal of Clinical Oncology 2003; 21: 593-601.
  • 32. Parmigiani G, Berry DA, Aguilar O. Determining carrier probabilities for breast cancer susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998; 62: 145-158.
  • 33. Bluman LG, Rimer BK, Berry DA, Borstelmann N, Iglehart JD, Regan K, Schildkraut J, Winer EP. Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol 1999; 17: 1040-1046.
  • 34. Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002; 20: 2701-2712.
  • 35. Geller G, Bernhardt BA, Doksum T, Helzlsouer KJ, Wilcox P, Holtzman NA. Decision-making about breast cancer susceptibility testing: How similar are the attitudes of physicians, nurse practitioners, and atriskwomen? J Clin Oncol 1998; 16: 2868-2876.
  • 36. Dorval M, Patenaude AF, Schneider KA, Kieffer SA, DiGianni L, Kalkbrenner KJ, Bromberg JI, Basili LA, Calzone K, Stopfer J, Weber BL, Garber JE. Anticipated versus actual emotional reactions to disclosure of results of genetic testsfor cancer susceptibility: findings from p53 and BRCA1 testing programs. J Clin Oncol 2000; 18: 2135-2142.
  • 37. Shattuck-Eidens D, OliphantA, McClure Metal. BRCA1 sequence analysis in women at high risk for susceptibility mutations. JAMA 1997; 278: 1242-1250.
  • 38. Blackwood A, Weber B. BRCA1 and BRCA2: From molecular genetics to clinical medicine. J Clin Oncol 1998; 16: 1969-1977.
  • 39. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108: 171-182.
  • 40. Brody L, Biesecker B. Breast cancer susceptibility genes, BRCA1 and BRCA2. Medicine 1998; 77: 208-226.
  • 41. Peelan T, van Viet M, Petrij-Bosch A, Mieremet R, Szabo C, van den Ouweland AM, Hogervorst F, Brohet R, Ligtenberg MJ, Teugels E, van der Luijt R, van der Hout AH, Gille JJ, Pals G, Jedema I, Olmer R, van Leeuwen I, Newman B, Plandsoen M, van der Est M, Brink G, Hageman S, Arts PJ, Bakker MM, Devilee P, et al. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian families. Am J Hum Genet 1997; 60: 1041-1049.
  • 42. Arason A, Jonasdottir A, Barkardottir R, Ergthorsson JT, Teare MD, Easton DF, Egilsson V. A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: Two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland. J Med Genet 1998; 35: 446-449.
  • 43. Garber J, Goldstein A, Kantor A, Dreyfus MG, Fraumeni JF Jr, Li FP. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 1991; 51: 6094-6097.
  • 44. Wong S, Lozano G, Gaff C, Gardner RJ, Strong LC, Aittomäki K, Lindeman GJ.. Novel p53 germline mutation in a patient with Li- Fraumeni syndrome. Intern Med J 2003; 33: 621.
  • 45. Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998; 90: 606-611.
  • 46. Eng C. Genetics of Cowden syndrome: Through the looking glass of oncology. Int J Oncol 1998; 12: 701-710.
  • 47. Hall J, Lee M, Newman B, Morrow JE, Anderson LA, Huey B, King MC. Linkage of early onset familial breast cancer to chromosome 17q21. Science 1990; 250: 1684-1685.
  • 48. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. Am J Hum Genet 1993; 52: 678-701.
  • 49. Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, Stratton MR, Easton D. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997; 15: 103-105.
  • 50. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994; 265: 2088-2090.
  • 51. Kirchhoff T, Kauff ND, Mitra N, Nafa K, Huang H, Palmer C, Gulati T, Wadsworth E, Donat S, Robson ME, Ellis NA, Offit K. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 2004; 10: 2918-2921.
  • 52. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004; 22: 735-742.
  • 53. Kelsey JL, Fischer DB, Holford TR, LiVoisi VA, Mostow ED, Goldenberg IS, White C. Exogenous estrogens and other factors in the epidemiology of breast cancer. J Natl Cancer Inst 1981; 67: 327-333.
  • 54. John EM, Kelsey JL. Radiation and other environmental exposures and breast cancer. Epidemiol Rev 1993; 15: 157-162.
  • 55. Ronckers CM, Erdmann CA, Land CE. Radiation and breast cancer: a review of current evidence. Breast Cancer Res 2005; 7: 21-32.
  • 56. John EM, Phipps AI, Knight JA, Milne RL, Dite GS, Hopper JL, Andrulis IL, Southey M, Giles GG, West DW, Whittemore AS. Medical radiation exposure and breast cancer risk: findings from the Breast Cancer Family Registry. Int J Cancer 2007; 121: 386.
  • 57. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A; WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women’s health initiative randomized trial. JAMA 2003; 289: 3243-3253.
  • 58. Million Women Study Collaborators. Breast cancer and hormonereplacement therapy in the million women study. Lancet 2003; 362: 419-427.
  • 59. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996; 347: 1713.
  • 60. Hankinson SE, Colditz GA, Manson JE, Willett WC, Hunter DJ, Stampfer MJ, Speizer FE. A prospective study of oral contraceptive use and risk of breast cancer. Cancer Causes Control 1997; 8: 65-72.
  • 61. Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, Bernstein L, Malone KE, Ursin G, Strom BL, Norman SA, Wingo PA, Burkman RT, Berlin JA, Simon MS, Spirtas R, Weiss LK. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346: 2025-2032.
  • 62. Terry MB, Zhang FF, Kabat G, Britton JA, Teitelbaum SL, Neugut AI, Gammon MD. Lifetime alcohol intake and breast cancer risk. Ann Epidemiol. 2006; 16: 230-240.
  • 63. Suzuki R, Ye W, Rylander-Rudqvist T, Saji S, Colditz GA, Wolk A. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study. J Natl Cancer Inst. 2005; 97: 1601-1608.
  • 64. Mahoney MC, Bevers T, Linos E, Willett WC. Opportunities and strategies for breast cancer prevention through risk reduction. CA Cancer J Clin. 2008; 58: 347-371.
  • 65. Howard RA, Leitzmann MF, Linet MS, Freedman DM. Physical activity and breast cancer risk among pre- and postmenopausal women in the U.S. Radiologic Technologists cohort. Cancer Causes Control. 2009; 20(3): 323-333.
  • 66. Lahmann PH, Friedenreich C, Schuit AJ, Salvini S, Allen NE, Key TJ, Khaw KT, Bingham S, Peeters PH, Monninkhof E, Bueno-de-Mesquita HB, Wirfält E, Manjer J, Gonzales CA, Ardanaz E, Amiano P, Quirós JR, Navarro C, Martinez C, Berrino F, Palli D, Tumino R, Panico S, Vineis P, Trichopoulou A, Bamia C, Trichopoulos D, Boeing H, Schulz M, Linseisen J, Chang- Claude J, Chapelon FC, Fournier A, Boutron-Ruault MC, Tjønneland A, Føns Johnson N, Overvad K, Kaaks R, Riboli E. Physical activity and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev. 2007; 16: 36-42.
  • 67. Tehard B, Friedenreich CM, Oppert JM, Clavel-Chapelon F. Effect of physical activity on women at increased risk of breast cancer: results from the E3N cohort study. Cancer Epidemiol Biomarkers Prev. 2006; 15: 57-64.
  • 68. Bernstein L, Patel AV, Ursin G, Sullivan-Halley J, Press MF, Deapen D, Berlin JA, Daling JR, McDonald JA, Norman SA, Malone KE, Strom BL, Liff J, Folger SG, Simon MS, Burkman RT, Marchbanks PA, Weiss LK, Spirtas R. Lifetime recreational exercise activity and breast cancer risk among black women and white women. J Natl Cancer Inst. 2005; 97: 1671-1679.
  • 69. Cho E, Chen WY, Hunter DJ, Stampfer MJ, Colditz GA, Hankinson SE, Willett WC. Red meat intake and risk of breast cancer among premenopausal women. Arch Intern Med 2006; 166: 2253-2259.
  • 70. Taylor EF, Burley VJ, Greenwood DC, Cade, JE. Meat consumption and risk of breast cancer in the UK Women’s Cohort Study. Br J Cancer 2007; 96: 1139-1146.
  • 71. Linos E, Willett WC. Diet and breast cancer risk reduction. J Natl Compr Canc Netw. 2007; 5: 711-718.
  • 72. Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, Hankinson SE. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1991-1997.
  • 73. Lin J, Cook NR, Albert C, Zaharris E, Gaziano JM, Van Denburgh M, Buring JE, Manson JE. Vitamins C and E and beta carotene supplementation and cancer risk: a randomized controlled trial. J Natl Cancer Inst 2009; 101: 14-23.
  • 74. Kushi LH, Fee RM, Sellers TA, Zheng W, Folsom AR. Intake of vitamins A, C, and E and postmenopausal breast cancer. The Iowa Women’s Health Study. Am J Epidemiol 1996; 144: 165-174.
  • 75. Ganmaa D, Willett WC, Li TY, Feskanich D, van Dam RM, Lopez-Garcia E, Hunter DJ, Holmes MD. Coffee, tea, caffeine and risk of breast cancer: a 22-year follow-up. Int J Cancer 2008; 122: 2071-2076.
  • 76. Ishitani K, Lin J, Manson JE, Buring JE, Zhang SM. Caffeine consumption and the risk of breast cancer in a large prospective cohort of women. Arch Intern Med 2008; 168: 2022-2031.
  • 77. Reynolds P, Hurley S, Goldberg DE, Anton-Culver H, Bernstein L, Deapen D, Horn-Ross PL, Peel D, Pinder R, Ross RK, West D, Wright WE, Ziogas A. Active smoking, household passive smoking, and breast cancer: evidence from the California Teachers Study. J Natl Cancer Inst 2004; 96: 29-37.
  • 78. Cui Y, Miller AB, Rohan TE. Cigarette smoking and breast cancer risk: update of a prospective cohort study. Breast Cancer Res Treat 2006; 100: 293-299.
  • 79. Al-Delaimy WK, Cho E, Chen WY, Colditz G, Willet WC. A prospective study of smoking and risk of breast cancer in young adult women. Cancer Epidemiol Biomarkers Prev 2004; 13: 398-404.
  • 80. Lissowska J, Brinton LA, Zatonski W, Blair A, Bardin-Mikolajczak A, Peplonska B, Sherman ME, Szeszenia-Dabrowska N, Chanock S, García-Closas M. Tobacco smoking, NAT2 acetylation genotype and breast cancer risk. Int J Cancer 2006; 119: 1961-1969.
  • 81. McElroy JA, Shafer MM, Trentham-Dietz A, Hampton JM, Newcomb PA. Cadmium exposure and breast cancer risk. J Natl Cancer Inst 2006; 98: 869-873.
  • 82. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA 2006; 296: 193-201.
  • 83. Degnim AC, Visscher DW, Berman HK, Frost MH, Sellers TA, Vierkant RA, Maloney SD, Pankratz VS, de Groen PC, Lingle WL, Ghosh K, Penheiter L, Tlsty T, Melton LJ 3rd, Reynolds CA, Hartmann LC. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol 2007; 25: 2671-2677.
  • 84. Noguchi S, Kasugai T, Miki Y, Fukutomi T, Emi M, Nomizu T. Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women. Cancer 1999; 85: 2200–2205.
  • 85. Marcus JN, Watson P, Page DL, Narod SA, Tonin P, Lenoir GM, Serova O, Lynch HT. BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res Treat 1997; 44: 275–277.
  • 86. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, Linder- Stephenson L, Salerno G, Conway TA, Lynch HT. Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996; 77: 697–709.
  • 87. Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Wagner A, van den Ouweland A, Devilee P, Meijers-Heijboer EJ, Klijn JG. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998; 351: 316–321.
  • 88. Armes JE, Egan AJ, Southey MC, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ. The histological phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations. A population-based study. Cancer 1998; 83: 2335–2345.
  • 89. Lakhani SR, Easton DF, Stratton MR, and the Breast Cancer Linkage Consortium. Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997; 349: 1505–1510.
  • 90. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrió D, Barroso A, Rodríguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Sánchez L, Rivas C, Benítez J. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: Differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 2003; 9: 3606–3614.
  • 91. Moinfar F, Man YG, Lininger RA, Bodian C, Tavassoli FA. Use of keratin 35BE12 as an adjunct in the diagnosis of mammary intraepithelial neoplasia-ductal type—Benign and malignant intraductal proliferations. Am J Surg Pathol 1999; 23: 1048–1058.
  • 92. Devilee P, Tavassoli FA. World Health Organization: Tumours of the Breast and Female Genital Organs. Lyon. IARC Press 2003.
  • 93. Fisher B. Tamoxifen in treatment of intraductal breast cancer: National surgical adjuvant breast and bowel project B-24 randomized controlled trial. Lancet 1999; 353: 1993.
  • 94. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S, Yaffe MJ. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007; 356: 227-336.
  • 95. Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ, Paterson AD.. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 2005; 6: 798-808.
  • 96. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 1159.
  • 97. Kuhl CK, Schmutzler RK, Leutner CC, Kempe A, Wardelmann E, Hocke A, Maringa M, Pfeifer U, Krebs D, Schild HH. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 2000; 215: 267–279.
  • 98. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292: 1317–1325.
  • 99. Podo F, Sardanelli F, Canese R, D’Agnolo G, Natali PG, Crecco M, Grandinetti ML, Musumeci R, Trecate G, Bergonzi S, De Simone T, Costa C, Pasini B, Manuokian S, Spatti GB, Vergnaghi D, Morassut S, Boiocchi M, Dolcetti R, Viel A, De Giacomi C, Veronesi A, Coran F, Silingardi V, Turchett D, Cortesi L, De Santis M, Federico M, Romagnoli R, Ferrari S, Bevilacqua G, Bartolozzi C, Caligo MA, Cilotti A, Marini C, Cirillo S, Marra V, Martincich L, Contegiacomo A, Pensabene M, Capuano I, Burgazzi GB, Petrillo A, Bonomo L, Carriero A, Mariani- Costantini R, Battista P, Cama A, Palca G, Di Maggio C, D’Andrea E, Bazzocchi M, Francescutti GE, Zuiani C, Londero V, Zunnui I, Gustavino C, Centurioni MG, Iozzelli A, Panizza P, Del Maschio A. The Italian multi-center project on evaluation of MR and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res 2002; 21: 115–124.
  • 100. Lehman CD, Isaacs C, Schnall MD, Pisano ED, Ascher SM, Weatherall PT, Bluemke DA, Bowen DJ, Marcom PK, Armstrong DK, Domchek SM, Tomlinson G, Skates SJ, Gatsonis C. Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology 2007; 244: 381-388.
  • 101. Nothacker M, Duda V, Hahn M, Warm M, Degenhardt F, Madjar H, Weinbrenner S, Albert US. Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue. A systematic review. BMC Cancer 2009; 9: 335.
  • 102. Dershaw DD. Mammographic screening of the high-risk woman. Am J Surg 2000; 180: 288–289.
  • 103. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001; 358: 1389–1399.
  • 104. National Comprehensive Cancer Network. National clinical practice guidelines in oncology: Breast cancer screening and diagnosis. Version 1, 2008.
  • 105. Berg WA. Tailored supplemental screening for breast cancer: what now and what next? AJR Am J Roentgenol 2009; 192: 390-399.
  • 106. Landier W, Bhatia S, Eshelman DA, Forte KJ, Sweeney T, Hester AL, Darling J, Armstrong FD, Blatt J, Constine LS, Freeman CR, Friedman DL, Green DM, Marina N, Meadows AT, Neglia JP, Oeffinger KC, Robison LL, Ruccione KS, Sklar CA, Hudson MM. Development of risk-based guidelines for pediatric cancer survivors: the Children’s Oncology Group Long-Term Follow-Up Guidelines from the Children’s Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 22: 4979–4990.
  • 107. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137: 347–360.
  • 108. Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001; 285: 2750–2756.
  • 109. Bassett L, Kimme-Smith C: Breast sonography. Am J Radiol 1991, 156: 449-456.
  • 110. Jackson VP: The role of US in breast imaging. Radiology 1990, 177: 305.
  • 111. SIGN Scottish Intecollegiate Guideline Network: SIGN Scottish Intecollegiate Guideline Network. Management of breast cancer in women Edinburgh: SIGN; 2005.
  • 112. NCCN National Comprehensive Cancer Network: Breast cancer screening and diagnosis guidelines USA: NCCN Clinical Practice Guidelines in Oncology; 2007.
  • 113. Albert US, Altland H, Duda V, Engel J, Geraedts M, Heywang- Köbrunner S, Hölzel D, Kalbheim E, Koller M, König K, Kreienberg R, Kühn T, Lebeau A, Nass-Griegoleit I, Schlake W, Schmutzler R, Schreer I, Schulte H, Schulz-Wendtland R, Wagner U, Kopp I. 2008 update of the guideline early detection of breast cancer in Germany. J Cancer Res Clin Oncol 2009; 135: 339-354.
  • 114. Ma L, Fishell E, Wright B, Hanna W, Allan S, Boyd NF. Case-control study of factors associated with failure to detect breast cancer by mammography. J Natl Cancer Inst 1992, 84: 781-785.
  • 115. Mandelson MT, Oestreicher N, Porter PL. Breast density as a predictor of mammographic detection: comparison of intervaland screendetected cancers. J Natl Cancer Inst 2000; 92: 1081-1087.
  • 116. Roubidoux M, Bailey J, Wray L, Helvie M. Invasive cancers detected after breast cancer screening yielded a negative result: relationship of mammographic density to tumor prognostic factors. Radiology 2004, 230: 42-48.
  • 117. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S, Yaffe MJ. Mammographic density and the risk and detection of breast cancer. N Eng J Med 2007; 356: 227-236.
  • 118. Kolb TM, Lichy J, Newhouse JH. Occult cancer in women with dense breasts: detection with screening US—diagnostic yield and tumor characteristics. Radiology 1998; 207: 191–199.
  • 119. Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology 2002; 225: 165–175.
  • 120. Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Böhm- Vélez M, Pisano ED, Jong RA, Evans WP, Morton MJ, Mahoney MC, Larsen LH, Barr RG, Farria DM, Marques HS, Boparai K; ACRIN 6666 Investigators. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA 2008; 299: 2151-2163.
  • 121. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG; Magnetic Resonance Imaging Screening Study Group. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351: 427–437.
  • 122. Kuhl CK, Schrading S, Leutner CC, Mora kkabati-Spitz N, Wardelmann E, Fimmers R, Kuhn W, Schild HH. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005; 23: 8469–8476.
  • 123. Leach MO, Boggis CR, Dixon AK, Easton D F, Eeles RA, Evans DG, Gilbert FJ, Griebsch I, Hoff RJ, Kessar P, Lakhani SR, Moss SM, Nerurkar A, Padhani AR, Pointon LJ, Thompson D, Warren RM; MARIBS study group. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365: 1769–1778.
  • 124. Lehman CD, Blume JD, Weatherall P, Thickm an D, Hylton N, Warner E, Pisano E, Schnitt SJ, Gatsonis C, Schnall M, DeAngelis GA, Stomper P, Rosen EL, O’Loughlin M, Harms S, Bluemke DA; International Breast MRI Consortium Working Group. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 2005; 103: 1898–1905.
  • 125. Debbie S, Carla B, Wylie B, et al (on beh alf of for the American Cancer Society Breast Cancer Advisory Group). American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography. CA Cancer J Clin 2007; 57: 75-89.
  • 126. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 1987; 2: 171–175.
  • 127. Preliminary analysis by the CRC Adjuvant Breast Trial Working Party. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party. Br J Cancer 1988; 57: 604–607.
  • 128. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320:479–484.
  • 129. Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Hjalmar ML, et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 1991; 83: 1299–1306.
  • 130. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687–1717.
  • 131. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371–1388.
  • 132. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97: 1652–1662.
  • 133. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B; National Surgical Adjuvant Breast and Bowel Project. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001; 286: 2251–2556.
  • 134. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98–101.
  • 135. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361: 296–300.
  • 136. Powles TJ, Sahley S, Tidy A, Smith IE, Dowsett M. Twenty-year followup of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007; 99: 283–290.
  • 137. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998; 352: 93–97.
  • 138. Veronesi U, Maisonneuve P, Sacchini V, Rotmensz N, Boyle P; Italian Tamoxifen Study Group. Tamoxifen for breast cancer among hysterectomised women. Lancet 2002; 359: 1122–1124.
  • 139. Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, Costa A, Sacchini V, Travaglini R, D’Aiuto G, Oliviero P, Lovison F, Gucciardo G, del Turco MR, Muraca MG, Pizzichetta MA, Conforti S, Decensi A; Italian Tamoxifen Study Group. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 2007; 99: 727–737.
  • 140. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T; IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002; 360: 817–8141.
  • 141.Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A; International Breast Cancer Intervention Study I Investigators. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007; 99: 272–282.
  • 142. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637–645.
  • 143. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281: 2189–2197.
  • 144. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR; CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751–1761.
  • 145. Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, Pajon ER, Wade JL 3rd, Dakhil S, Lockhart JB Jr, Wolmark N, Ganz PA. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2742–2751.
  • 146. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK; Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125–137.
  • 147. Grady D, Cauley JA, Geiger MJ, Kornitzer M, Mosca L, Collins P, Wenger NK, Song J, Mershon J, Barrett-Connor E; Raloxifene Use for The Heart Trial Investigators. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J Natl Cancer Inst 2008; 100: 854–861.
  • 148. Baum M, Budzar A, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T; ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131–2139.
  • 149. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T; ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of potmenopausal women with early-breast cancer: results of ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98: 1802–1810.
  • 150. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081–1092.
  • 151. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793–1802.
  • 152. Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, Petty PM, Sellers TA, Johnson JL, McDonnell SK, Frost MH, Jenkins RB. Efficacy of bilateral prophylactic mastectomy in womwn with a family history of breast cancer. N Eng J Med 1999; 340: 77-84.
  • 153. Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, Frost MH, Grant CS, Donohue JH, Woods JE, McDonnell SK, Vockley CW, Deffenbaugh A, Couch FJ, Jenkins RB. Efficacy of bilateral prophylactic mastectomy in BRCA 1 and BRCA 2 gene mutation carriers. J Natl Cancer Ins 2001; 93: 1633-1637.
  • 154. Meijers-Heijboer H, van Geel B van Putten WL, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG. Breast cancer after bilateral prophylactic mastectomy in women with BRCA 1 and BRCA 2 mutation. N Eng J Med 2001; 345: 159-164.
  • 155. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van ‘t Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL. Bilateral prophylactic mastectomy reduces the risk in BRCA 1 and BRCA 2 mutation carriers; the PROSE Study Group. J Clin Oncol 2 004; 22: 1055-1062.
  • 156. Borgen PI, Hill AD, Tran KN, Van Zee KJ, Massie MJ, Payne D, Biggs CG. Patient regrets after bilateral prophylactic mastectomy. Ann Surg Oncol 1998; 5: 603–606.
  • 157. Jameson MB, Roberts E, Nixon J, Probert JC, Braatvedt GD. Metastatic breast cancer 42 years after bilateral subcutaneous mastectomies. Clin Oncol 1997; 9: 119-121.
  • 158. Zion S, Slezak J, Schaid D, Woods JE, Arnold PG, Petty PM, Donohue JH, Frost MH, Schaid DJ, Hartmann LC. Reoperations after prophylactic mastectomy with or without implant reconstruction. Cancer 2003; 98: 2152-2160.
  • 159. Gabriel S, Woods J, O’Fallon M, Beard CM, Kurland LT, Melton LJ 3rd. Complications leading to surgery after breast implantation. N Engl J Med 1997; 336: 677–682.
  • 160. Stefanek ME, Helzlsouer KJ, Wilcox PM, Houn F. Predictors of satisfaction with bilateral prophylacticmastectomy. Preventative Medicine 1995; 24: 412–419.
  • 161. Josephson U, WickmanM, Sandelin K. Initial experiences of women from hereditary breast cancer families after bilateral prophylacticmastectomy: a retrospective study. Eur J Cancer 2000; 26: 351–356.
  • 162. Peralta E, Ellenhorn J, Wagman L, Dagis A, Andersen JS, Chu DZ. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 2000; 180: 439–445.
  • 163. Lee JS, Grant CS, Donohue JH, Crotty TB, Harmsen WS, Ilstrup DM. Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer. Surgery 1995; 118: 640–647.
  • 164. Babiera GV, Lowy AM, Davidson BS, Singletary SE. The role of contralateral prophylacticmastectomy in invasive lobular carcinoma. Breast Journal 1997; 3: 2–6.
  • 165. McDonnell SK, Schaid DJ, Myers JL, Grant CS, Donohue JH, Woods JE, Frost MH, Johnson JL, Sitta DL, Slezak JM, Crotty TB, Jenkins RB, Sellers TA, Hartmann LC. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. Journal of Clinical Oncology 2001; 19: 3938–3943.
  • 166. Montgomery L, Tran K, Heelan M, Van Zee KJ, Massie MJ, Payne DK, Borgen PI. Issues of regret in women with contralateral prophylactic mastectomies. Annals of Surgical Oncology 1999; 6: 546–552.
  • 167. Kollias J, Ellis IO, Elston CW, Blamey RW. Clinical and histological predictors of contralateral breast cancer. Eur J Surg Oncol 1999; 25: 584-589.
  • 168. Olopade OI, Artioli G. Efficacy of risk-reducing salpingooophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J 2004; 10: 5-9.
  • 169. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL. Breast cancer rsik after bilateral oopherectomy in BRCA 1 mutation carrieres. J Natl Cancer Inst 1999; 91: 1474–1479.
  • 170. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101: 80-87.
  • 171. Michelsen TM, Dørum A, Dahl AA. A controlled study of mental distress and somatic complaints after risk-reducing salpingooophorectomy in women at risk for hereditary breast ovarian cancer. Gynecol Oncol 2009; 113: 128-133.
  • 172. Kauff ND, Barakat RR. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol 2007; 25: 2921-2927.
APA KOÇAK Ş, ÇELİK L, ÖZBAŞ S, SAKA D, TÜKÜN A, Yalçın B (2011). Meme kanserinde risk faktörleri, riskin değerlendirilmesi ve prevansiyon: İstanbul 2010 konsensus raporu. , 47 - 67.
Chicago KOÇAK Ş.,ÇELİK L.,ÖZBAŞ S.,SAKA DİZDAY S.,TÜKÜN A.,Yalçın B. Meme kanserinde risk faktörleri, riskin değerlendirilmesi ve prevansiyon: İstanbul 2010 konsensus raporu. (2011): 47 - 67.
MLA KOÇAK Ş.,ÇELİK L.,ÖZBAŞ S.,SAKA DİZDAY S.,TÜKÜN A.,Yalçın B. Meme kanserinde risk faktörleri, riskin değerlendirilmesi ve prevansiyon: İstanbul 2010 konsensus raporu. , 2011, ss.47 - 67.
AMA KOÇAK Ş,ÇELİK L,ÖZBAŞ S,SAKA D,TÜKÜN A,Yalçın B Meme kanserinde risk faktörleri, riskin değerlendirilmesi ve prevansiyon: İstanbul 2010 konsensus raporu. . 2011; 47 - 67.
Vancouver KOÇAK Ş,ÇELİK L,ÖZBAŞ S,SAKA D,TÜKÜN A,Yalçın B Meme kanserinde risk faktörleri, riskin değerlendirilmesi ve prevansiyon: İstanbul 2010 konsensus raporu. . 2011; 47 - 67.
IEEE KOÇAK Ş,ÇELİK L,ÖZBAŞ S,SAKA D,TÜKÜN A,Yalçın B "Meme kanserinde risk faktörleri, riskin değerlendirilmesi ve prevansiyon: İstanbul 2010 konsensus raporu." , ss.47 - 67, 2011.
ISNAD KOÇAK, Ş. vd. "Meme kanserinde risk faktörleri, riskin değerlendirilmesi ve prevansiyon: İstanbul 2010 konsensus raporu". (2011), 47-67.
APA KOÇAK Ş, ÇELİK L, ÖZBAŞ S, SAKA D, TÜKÜN A, Yalçın B (2011). Meme kanserinde risk faktörleri, riskin değerlendirilmesi ve prevansiyon: İstanbul 2010 konsensus raporu. Meme Sağlığı Dergisi, 7(2), 47 - 67.
Chicago KOÇAK Ş.,ÇELİK L.,ÖZBAŞ S.,SAKA DİZDAY S.,TÜKÜN A.,Yalçın B. Meme kanserinde risk faktörleri, riskin değerlendirilmesi ve prevansiyon: İstanbul 2010 konsensus raporu. Meme Sağlığı Dergisi 7, no.2 (2011): 47 - 67.
MLA KOÇAK Ş.,ÇELİK L.,ÖZBAŞ S.,SAKA DİZDAY S.,TÜKÜN A.,Yalçın B. Meme kanserinde risk faktörleri, riskin değerlendirilmesi ve prevansiyon: İstanbul 2010 konsensus raporu. Meme Sağlığı Dergisi, vol.7, no.2, 2011, ss.47 - 67.
AMA KOÇAK Ş,ÇELİK L,ÖZBAŞ S,SAKA D,TÜKÜN A,Yalçın B Meme kanserinde risk faktörleri, riskin değerlendirilmesi ve prevansiyon: İstanbul 2010 konsensus raporu. Meme Sağlığı Dergisi. 2011; 7(2): 47 - 67.
Vancouver KOÇAK Ş,ÇELİK L,ÖZBAŞ S,SAKA D,TÜKÜN A,Yalçın B Meme kanserinde risk faktörleri, riskin değerlendirilmesi ve prevansiyon: İstanbul 2010 konsensus raporu. Meme Sağlığı Dergisi. 2011; 7(2): 47 - 67.
IEEE KOÇAK Ş,ÇELİK L,ÖZBAŞ S,SAKA D,TÜKÜN A,Yalçın B "Meme kanserinde risk faktörleri, riskin değerlendirilmesi ve prevansiyon: İstanbul 2010 konsensus raporu." Meme Sağlığı Dergisi, 7, ss.47 - 67, 2011.
ISNAD KOÇAK, Ş. vd. "Meme kanserinde risk faktörleri, riskin değerlendirilmesi ve prevansiyon: İstanbul 2010 konsensus raporu". Meme Sağlığı Dergisi 7/2 (2011), 47-67.